Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

Not Applicable

Conditions: Stage IV Ovarian Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer
Stage IV Renal Cell Cancer
Stage IV Liver Cancer
Stage IV Small Intestinal Cancer
Recurrent Malignant Solid Neoplasm
Stage IV Breast Cancer
Stage IV Pancreatic Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Device: Canady Helios Cold Plasma Scalpel

Registration Number: NCT04267575

Lead Sponsor: Jerome Canady, M.D.

Brief Summary: The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection).. Plasma is an ionized gas typically generated in high-temperature laboratory conditions. Plasma coagulators are currently used routinely as surgical tools with multiple applications that create temperatures between 37° C to 43°C and cause thermal injury. Earlier studies demonstrated the non-aggressive nature of cold plasma. As evidence accumulates, it is becoming clear that low-temperature cold plasma has an increasing role in biomedical applications.

Detailed Description: Not available

Recruitment & Eligibility

Status: UNKNOWN

Sex: All

Target Recruitment: 20

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

Solid tumors undergoing surgical treatment with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection).
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study and must be willing to return for follow-up
18 years of age or older and capable of providing informed consent indicating awareness of the investigational nature of this trial, in keeping with Good Clinical Practice (GCP) guidelines and institutional policy.
Biopsy (histopathology or cytology) diagnosis of a solid tumor as defined by the World Health Organization (WHO) or by cross-sectional imaging reviewed by a board-certified radiologist.
Good performance status (ECOG < 2), Karnofsky >60%,
Patients with low or acceptable surgical risk (American society of Anesthesiology (ASA) score of 3 or less.
Patient is a candidate for surgical therapy as discussed and recommended by the institutional disease management team (DMT, Tumor Board).

At the time of enrollment:

Absolute neutrophil count (ANC) exceeds 1200/mm3, white blood cell count exceeds 4000/mm3 and platelet count is greater than 100,000/mm3
An international normalized ratio (INR) ≤ 1.5 (patients who are therapeutically anticoagulated for non-related medical conditions such as atrial fibrillation and whose anti-thrombotic treatment can be withheld for operation will be eligible).
Adequate hepatic function must be met as evidenced by total serum bilirubin ≤ 3.0 mg/dl ; alkaline phosphatase < 2.5 times the upper limit of normal; and, aspartate aminotransferase (AST) less than 1.5 times upper limit of normal [alkaline phosphatase and AST cannot both exceed the upper limit of normal]
Serum renal functional parameters, blood urea nitrogen (BUN) and creatinine are within normal limits
For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
Life expectancy of at least six months

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

Patients with unresectable tumors as decided by a multidisciplinary disease management team
Patients with multiple metastatic sites not amenable for surgical resection
Pregnancy or lactation
Patients with low performance status (ECOG > 2 or Karnofsky < 60%)
Any one or more of the following hematological abnormalities
Hgb < 8gm/dl unable to be corrected with transfusion
Absolute Neutrophil Count < 1200/mm3
White blood cell count < 4000/mm3
Platelet count < 100,000/mm3
INR > 1.5 (except in patients who are therapeutically AST anticoagulated for non-related medical conditions such as atrial fibrillation and whose anti-thrombotic treatment cannot be withheld for operation will be eligible)
History of hepatic cirrhosis or present hepatic dysfunction
Alkaline phosphatase ≥ 2.5 times the upper limit of normal
≥ 1.5 times upper limit of normal
Serum bilirubin > 3.0 mg/dl
Alkaline phosphatase and AST both exceed the upper limit of normal
Renal insufficiency indicated by a serum creatinine >1.5mg/dL.
Patients with high surgical risk (ASA 4-5) with significant history of a medical problem that would preclude the patient from undergoing an operative procedure such as a history of severe congestive heart failure or active ischemic heart disease.
Febrile illness within 7 days before scheduled surgery
Treatment with another investigational drug or other intervention within 60 days before surgery
Patients that are unable to- or unwilling to provide a written informed consent
Patients who underwent treatment with cold plasma within a year before study entry.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Primary Arm	Canady Helios Cold Plasma Scalpel	After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Complications Due To Cold Plasma Application	Immediate after application of cold plasma, followed by 3 months, 6 months, 12 months and 15 month observations.	Adverse events (CTCAE event version 4.03 to 5.0) within 30 days after Canady Helios Cold Plasma Scalpel treatment.

Secondary Outcome Measures